Biotechnology

Tharimmune To Participate in Two Upcoming Investor Conferences in May

April 30, 2024 8:31 AM

BRIDGEWATER, NJ / ACCESSWIRE / April 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology announced that management will be participating in two investor conferences in May. Randy Milby, Chief Executive Officer, will be presenting at the Planet MicroCap Showcase: VEGAS 2024 being held at the Paris Hotel &...

Read more

Emmecell Completes Final Cell Therapy Dosing in U.S. Clinical Trial for Corneal Edema

April 30, 2024 7:00 AM

MENLO PARK, CA / ACCESSWIRE / April 30, 2024 / Emmetrope Ophthalmics LLC ("Emmecell"), a clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of serious eye diseases, today announced final dose administration for the last patient in its U.S. randomized, double-masked, multi-center trial assessing the safety and efficacy of EO2002 for the treatment of corneal edema. Emmecell Logo...

Read more

Moolec Announces New Patent Granting in the United States for Molecular Farming Platform

April 30, 2024 6:00 AM

LUXEMBOURG / ACCESSWIRE / April 30, 2024 / Moolec Science SA (NASDAQ:MLEC) ("Company"; "Moolec"), a Molecular Farming food-ingredient company, announced today the granting of a patent family in the United States for its SPC2 product produced in safflower with Molecular Farming technology. This new patent adjudication will give the company, through its U.S. sole-owned subsidiary AG Biomolecules LLC, exclusivity for the use of the technology until...

Read more

Genflow Biosciences PLC Announces Total Voting Rights

April 30, 2024 2:05 AM

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Total Voting Rights LONDON, UK /...

Read more

Biophytis is Deploying its Partnership Strategy in Obesity

April 29, 2024 9:00 AM

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 29, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces the implementation of a dedicated strategy for partner search in obesity. Biophytis is continually working on the search for partners thanks to a sound strategy and action plan,...

Read more

Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc.

April 29, 2024 7:00 AM

- The clinical assets to be acquired include cancer and ocular disease programs, including regulatory and clinical packages and access to Oncotelic's AI platform for identifying immunotherapy combinations HUNTINGTON BEACH, CA / ACCESSWIRE / April 29, 2024 / Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"), (OTC PINK:CPMV), a development-stage biotechnology company focused on the development of novel immunotherapies to treat and prevent...

Read more

Radiance Biopharma to Present at LSX World Congress 2024

April 26, 2024 12:10 PM

Radiance Biopharma ("Radiance" or the "Company"), a biopharmaceutical company specializing in the development of novel Antibody Drug Conjugates (ADCs) and Bispecific ADCs (BsADCs) treatments for cancers, today announced that Robert Brooks, JD, Chief Executive Officer of Radiance will present at the LSX World Congress 2024 on Monday, April 29, 2024 at 11:15AM (GMT+1) in London, England. In addition to the presentation, Mr. Brooks will be...

Read more

Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

April 25, 2024 9:45 AM

JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Moleculin Biotech (NASDAQ:MBRX), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses. Watch the "What This Means" video here As part of this "What This Means" segment, Walter Klemp, Chairman and Chief Executive...

Read more

TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

April 25, 2024 9:00 AM

TAMPA, FL and SAN DIEGO, CA / ACCESSWIRE / April 25, 2024 / TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that its IFx-2.0 Phase 1b clinical trial results have been accepted for poster presentation at the 2024 ASCO Annual Meeting taking place May 31-June 4, 2024 in Chicago, IL. Details of the presentation are...

Read more

Ondine Biomedical Inc Announces New Study Confirms Nose Is Key Source of Infection

April 25, 2024 2:00 AM

Ondine Biomedical Inc. (LON:OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, announces new independent research published in the journal Science Translational Medicine showing that 86% of surgical site infections (SSIs)! after spinal surgery are caused by bacteria from the patient's own nose, skin, or gut. The study, "Contribution of the patient microbiome to surgical site infection and antibiotic...

Read more

Hemogenyx Pharmaceuticals PLC Announces Final Results

April 25, 2024 2:00 AM

Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces its final audited results for the year ended 31 December 2023. The Annual Report is available to view on the Company's web site at https://hemogenyx.com. Key Highlights · Investigational New Drug ("IND") application submitted in May 2023 seeking authorisation from the U.S. Food and Drug Administration...

Read more

Tiger Aesthetics Medical, LLC Acquires Assets of Sientra, Inc.

April 24, 2024 5:45 PM

Focus on Regenerative Medicine Combined with Best-in-Class Aesthetics Device Offering FRANKLIN, WI / ACCESSWIRE / April 24, 2024 / Tiger Aesthetics Medical, LLC today announced its acquisition of substantially all of the assets associated with the Sientra Inc. breast implant business. This strategic acquisition will complement Tiger Aesthetics' upcoming adipose cell and tissue product launches designed to provide new treatment options for...

Read more

Deverra Therapeutics Granted FDA Fast Track Designation for DVX101 (Dilanubicel) for the Treatment of Acute Myeloid Leukemia

April 24, 2024 4:30 PM

SEATTLE, WA / ACCESSWIRE / April 24, 2024 / Deverra Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic universal donor cell therapy treatments to fight cancer and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track (FT) designation to dilanubicel, the Company's lead candidate for the treatment of newly diagnosed acute myeloid leukemia (AML) to improve...

Read more

BioInvent to Present Clinical Data from its Two Leading Assets at ASCO 2024

April 24, 2024 10:20 AM

The two poster presentations will report - first combination data from the Phase 1/2a study with BI-1808 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as well as an update on monotherapy arm combination data from the Phase 1/2a study with BI-1206 in combination with KEYTRUDA for the treatment of patients with solid tumors Both BI-1808 and BI-1206 are first-in-class immunomodulatory agents with the potential to improve...

Read more

Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium

April 24, 2024 6:15 AM

Overall 8.46 Average Revised Venous Clinical Severity Score (rVCSS) Improvement Per Patient for Patients Showing Clinical Meaningful Benefit (rVCSS Improvement ≥ 3 Points) including: 9.29 Points for Patients at the Two-Year Milestone 8.08 Points for Patients at the One-Year Milestone 8.71 Points for Patients at the Six-Month Milestone 72% of the Study Patients Showing Clinical Meaningful Benefit from the VenoValve at a Weighted Average of 11...

Read more

BioInvent International AB: Interim Report January-March 2024

April 24, 2024 2:20 AM

LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / BioInvent International (STO:BINV) "During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023. Looking ahead in 2024, we are preparing for multiple data presentations for our six ongoing clinical programs." - Martin Welschof, CEO of BioInvent. EVENTS IN THE...

Read more

Biovica Saves SEK 30 Million/Year and Investigates New Go-To Market Model in US

April 23, 2024 10:15 AM

UPPSALA, SE / ACCESSWIRE / April 23, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in blood-based cancer monitoring, announces a cost reduction program in Sweden and the US that will result in annual cost savings of approximately SEK 30 million and a restructuring cost of SEK 8 million. At the same time, Biovica is investigating the opportunity to change its go-to-market model in the US from having its own...

Read more

Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health

April 23, 2024 9:15 AM

Collaboration with leading telemedicine provider to offer marketing and distribution of STENDRA for Lemonaid Health's ED patients (Please see important safety information below) NEW YORK, NY / ACCESSWIRE / April 23, 2024 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces a new collaboration with Lemonaid Health, leading...

Read more

Enzolytics Inc. Announces Dismissal of The Dimitar Savov Lawsuit in Nevada

April 23, 2024 8:30 AM

Enzolytics, Inc. (OTC PINK:ENZC) (enzolytics.com)(the "Company") today disclosed that on April 9, 2024, the US District Court of Nevada dismissed the lawsuit, 22-cv-00401-GMN-DJA brought by Dimitar Savov against IMMB bringing to an end the claims alleged in this suit. Originally filed on March 3, 2022 against the corporation that ENZC had its assets, including ITV-1, IMMB and ENZC have successfully defended their position against the plaintiff...

Read more

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

April 23, 2024 7:31 AM

Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology, announced today an option agreement for an exclusive license with Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The technology was...

Read more